Method of obtaining alpha-tocopheryl esters of 5-substituted picoline acid

专利摘要:
METHOD FOR OBTAINING OI-TOCOPHERYL ETHERS OF 5-SILETTED PICOLINIC ACID of the general formula I CHi RN (CHiCHiCHiCH) jCH, l HjC, JL, 0. CHjCHj N coo where R is C -Cj-alkyl, unsubstituted or substituted by hydroxy group, acetoxy group or halogen atom, lower alkenyl, phenyl (lower) alkyl or phenyl substituted by halogen atom, Q is methylene group or oxygen or sulfur atom, characterized by that a 5-substituted picolinic acid of the formula II K Q K SOOI where R and Q have the indicated values, or its acid halide reacts with an α (.-tocopherol in an organic solvent I medium and CO in the case of using an acid in C in the presence of a dehydrocondensing agent. Priority by featured: 05/26/81 with Q - methylene group, R - PROPIL or butyl on 13.04.82 with Q - methylene group or oxygen or sulfur atom, R - lower alkyl, unsubstituted or substituted, lower alkenyl, phenyl (lower) alkyl or substituted phenyl, provided that when R is propyl or butyl, Q is not a methylene group.
公开号:SU1151209A3
申请号:SU823443536
申请日:1982-05-25
公开日:1985-04-15
发明作者:Йано Мицуо；Йосизава Джунджи；Исикава Кийофуми；Харада Нобуо；Мацумото Икуо
申请人:Баниу Фармасьютикал Ко,Лтд (Фирма)；
IPC主号:

专利说明:

The invention relates to a process for the preparation of novel compounds - the ei-current of the 3-substituted polyol acid esters of the formula CH, HcC JlVo G iCH7CHiCH jGH, f TY CHj CHj.; R is C-Cj-alkyl, unsubstituted or substituted by hydroxy, acetoxy group or halogen atom, lower alkenyl, phenyl (lower) alkyl or phenyl substituted by halogen atom, Q is a methylene group or an oxygen or sulfur atom. These compounds reduce blood pressure, have high efficacy and long duration of action, and can be used for a long time for the prevention and treatment of hypertension while they have no side effects and have low toxicity. The 5-substituted picolinic acid derivatives are known, which are represented by 5-butyl picolinic acid, which reduce dopamine A-hydroxylase activity and lower blood pressure D3. However, the known 5-substituted picolinic acid derivatives. I have an acidic reaction and, if taken orally, can cause gastric diseases. Since these compounds are quite toxic, their use is limited. The method is based on the known esterification reaction of ci-tocopherol with an acid in the presence of a dehydrocondensing agent 21 or acid halide. The purpose of the invention is to obtain new derivatives of the 3-substituted picolinic acid esters of formula (I), which possess valuable pharmacologically active properties. This goal is achieved in that according to method 3-substituted picolinic acid of formula i COOH where K and Q have the indicated values, or its acid halide is reacted with d-tocopherol in an organic solvent medium and in the case of using an acid in the presence of a dihydrocondensing agent. Dicyclohexylcarbodiigdad or phosphorus oxychloride is preferably used as a dehydrocarbenzene. The process is carried out in an aprotic organic solvent, such as hexane, methylene chloride, chloroform, toluene, dimethylformamide, tetrahydrofuran or pyridine. The molar ratio between 5-substituted picolinic acid, o tocopherol and dehydrating condensing agent is, as a rule, 1.0: 0.5-5.0: 0.3-10.0, preferably 1.0: 0.8-1 , 5: 1.0-2.0, respectively. The resulting product can be isolated from the reaction mixture and purified by conventional methods, for example, solvent extraction, column chromatography or recrystallization. Typically, products insoluble in the reaction mixture are separated by filtration, and the filtrate is washed with dilute acid and dilute aqueous alkali metal bicarbonate solution. The desired product is then distilled off. If desired, it may be subjected to additional purification using preparative column chromatography or recrystallization. The starting compounds of formula (II) can be prepared, for example, by oxidation of 3-substituted d-picoline with selenium dioxide. It is preferable to carry out the oxidation reaction in pyridine. The reaction ends after boiling 1 mol of 5-substituted "A-picoline with 1.3-4.0 mol of selenium dioxide under reflux for 3-24 hours. Metallic selenium is then separated from the reaction mixture, and pyridine is distilled . The residue is dissolved in water and the solution is neutralized with an acid, as a result of which the 3-substituted picolinic acid is separated. Example 1. 3.6 g of 3-butyl picolinic acid and 4.3 g of dl-o (α-tocopherol are dissolved in 40 ml of methylene chloride) and a solution of 4.2 g of dicyclohexylcarbodiimide in 20 ml of methi-:
Lenchloride. The mixture is stirred at room temperature for 24 hours. The precipitate is filtered off: it is rolled and the methylene chloride is distilled off. The residue is dissolved in hexane, and the insoluble part is filtered off. The residue is subjected to chromatography on a column filled with silica gel. A mixture of benzene and ethyl acetate in the ratio 4: 1 is used as eluent. 5.5 g of dl-ci-tocopheryl-5-butilpicolinate are obtained as a yellowish oily liquid.
The results of elemental analysis.
Calculated,%: C 79.14, H 10.39 N 2.37. ;
Found,%: C 78.89, H 10.71, N 2.10.
IR spectrum - net max., Cm: 2920, 2885, 1755, 1725, 1570, 1460, 1300, 1240, 1100, 755.
UV spectrum, i ethanol, max., Nm: 227 (G 21700), 280 (f 8000). NMR spectrum Cd, 60 MHz), c-ppm: 0.73, 0 (t, 58H), 6.5 (1H), 8.0 (q, 1H), 8.5 (d, 1H) ..
Example 2 10 ml of benzene was added to 4.51 g of 5-butyl picolinic acid, after which another 9 g of thionyl chloride was added. The mixture was heated under reflux for 22 minutes. Then an excess of thionyl chloride and benzene was distilled off under reduced pressure, and 10 ml of benzene was added to the residue. The mixture is cooled to and stirred at this temperature. A solution of 5 g of dl-ot.-tocopherol in 4.25 ml of pyridine is added dropwise to the solution. The reaction is continued for 1 h 40 min. The precipitating precipitate is filtered off and the residue is washed successively with water, 1 n. hydrochloric acid, water, saturated sodium bicarbonate solution and saturated sodium chloride solution. The benzene was distilled off, and the residue was subjected to chromatography on a column filled with silica gel, using a mixture of benzene and ethyl acetate in a 4: 1 ratio as eluent. The result is 3.2 g 61-e / .- tocopheryl-5-butsh1 picolinate.
Example 3. The same operations as in Example 1 are repeated, with the difference that instead of .5-butyl picolinic acid, 3.8 g of 5-pentyl picolinic acid are used. In the result, 5.6 g of dl-5-pentyl picolinate are obtained in the form of a yellowish ma-liqueur liquid.
The results of elemental analysis. 5 Calculated,%: C 79.29, H 10.48, N 2.31.
C, oH, jN03
Found,%: C 79J6, H 10.85, N 1.96.
oIR spectrum, net max.,:
12920, 2850, 1750, 1725, 1570, 1460, 11300, 1100, 755.
UV spectrum, A ethanol, max., Nm: 227 (E 24400), 280 (8970). NMR spectrum (CCI, 60 MHz),
.i.pm: 0.6-3.0 (m, 60H), 7.59 (t, 1H), 8.0 (d, 2H), 8.5 (d, 1H).
Example 4. 2.42 g of 5- (3,4-dibromobutyl) picolinic acid,
2.15 g of dl-ii-tocopherol and 4.0 ml of triethylamine are dissolved in 15 ml of methylene chloride and a solution of 1.0 ml of phosphorus oxychloride in 5 ml of methylene chloride is added dropwise with stirring and ice-cooling. The reaction at this temperature is continued for 3 hours. After completion of the reaction, the reaction mixture is washed with 2N. salt
 acid, then water and dried. Methylene chloride is distilled off, and the residue is subjected to chromatography on a column filled with silica gel, using as eluent a mixture
5 benzene and ethyl acetate in the ratio 4: 1. As a result, 3.03 g of dl-oi-tocopheryl-5- (3,4-dibromic) -picolinate are obtained in the form of a yellowish oily liquid.
0 IR spectrum,) net max.: 2920, 2850, 1745, 1722, 1570, 1460, 1380, 1300, 1240, 1100, 704.
NMR spectrum (COCl3, 60 MHz), cGrp: 0.6-2.8 (t, 53H), 3.65 (d, 2H),
3.85-4.35 (t, 1H), 7.72 (q, 1H), 8.25 (d, W), 8.75 (d, W).
Thus, using, as in Example 4, dl-o (.- tocopherol and the corresponding 5-substituted picolinic acid) as starting materials, the following compounds are obtained.
Examples 5-9. dl-i-TokdfereSh1-5- (3,4-dichlorobutyl) -pikolinat
5 (example 5).
IR spectrum, t) net max., 2920, 2850, 1745, 1722, 1570, 1470, 1460, 1380, 1300, 1240, 1100, 760.
NMR spectrum (COClS, mHz), ppni: 0.6 2.8 (m, 53H), 3.7 (d, 2H), 3.854, 2 (m, 1H), 7.75 (q, 1H), 8.25 (d, 1H), 8.75 (d, 1H).
e1-o-tocopheryl-5- (4-6-butyl) picolinate (example 6),
IR spectrum, V pure max., Cm: 2920, 2820, 1750, 1720, 1465, 1460, 1375, 1300, 1240, 1100.
NMR spectrum (CDCl ,, 60 MHz), tfppm: 0, 6-2.9 (m, 55H), 3.4 (t, 2H), 7.75, (q, 1H), 8.2 (d , 1H), 8.65 (d, 1H).
dl-lz (-Tophosphin-5- (4-chlorobuty)) picolinate (example 7).
IR spectrum, -J net max., 2920, 2850, 1750, 1730, 1465, 1460, 1375, 1300, 1240, 1100,
NMR spectrum (CDC1,, 60), sLrt: 0.62, 9 (ha, 55H), 3.5 (t, 2H), 7.75 (q, W), 8.2 (d, 1H), 8.65 (d, 1H).
dl-o-Tocopheryl 5- (4-acetoxybutythyl) picolinate (Example 8).
IR spectrum, l) net max. Cm /: 2920, 2850, 1750, 1730, 1722, 1465, 1460, 1380, 1300, 1250, 1100, 1040.
NMR spectrum (CDCl1, 60 MHz), cGHp: 0 „6-3.0 (t, 55H), 2.05 (S, 3N), 4.1 (t, 2H), 7.7 (q, 1H ), 8.25 (d, 1H), 8.7 (d, 2H).
dl-oi-Tokofepil-5-benzylpikolinat (example 9) f,
IR spectrum, h: max, cm: 2920, 2850, 1750, 1725, 1600, 1570, 1460, 1310, 1240, 1100, 755.
Nuclear Magnetic Resonance Spectrum (CDCl1, 60 MHz), sGrrg: 0.6, 2.8 (t, 49H), 4.2 (s, 2H), 7.3 (s, 5H), 7.6 (q , 1H), 8.2 (d, 1H 8.6 (d, 1H).
Example 10. 3.92 g of 5- (4-hydroxy-butyl) -picolinic acid is dissolved in 20 ml of pyridine and added to the resulting solution with stirring and cooling with ice, dropwise 4.6 g of carbobenzyloxychloride in 20 ml of toluene. The reaction is carried out for 2 hours, cooling the mixture with ice. Then the reaction mixture was drunk in ice water and extraction was performed with toluene. The extract is washed with water, 1 n. hydrochloric acid and water again, after which toluene is distilled off. As a result, 5.7 5- (4-carbobenzyloxybutyl) -picolinic acid is obtained.
5.7 g of 5- (4-carbobenzyloxybutyl) picolinic acid and 7.7 g of dl-ii-Tocopherol are dissolved in 50 ml of methylene chloride and 7.5 g of dicyclohexylcarbodimide are added to the resulting solution. The mixture is left to stand overnight at room temperature. The precipitated dicyclohexyl urea is filtered off and methylene chloride is distilled off from the filtrate.
The residue was dissolved in 100 ml of ethanol and 1.5 g of 5% palladium on carbon was added to the resulting solution. The hydrogenation was carried out, a hydrogen stream was passed through the mixture for 3 hours at room temperature, the catalyst was filtered off and the ethanol was distilled off. The residue is subjected to chromatography on a column filled with silica gel, using as eluent a mixture of benzene and ethyl acetate in a 4: 1 ratio. The result is 2.18 g of dl-o (-TO Koferyl-5- (4-hydroxybutyl) picolinate as a yellowish oily liquid ..
IR spectrum, About net max.,:
3450, 2920, 2850, 1745, 1730, 1720,
1460, 1375, 1300, 1250, 1100, 1040.
NMR spectrum (CDCl1, 60 MHz), sGrrga: 0-3.0 (t, 55H), 2.9 (t, 1H), 3.8-4.2 (t, 2H), 7.7 (q , 1H), 8.25 (d, 1H), 8.7 (d, 1H).
Example 11, K3.8g of 5-ethyl picolinic acid was added 10 ml of toluene, and then 9 g of thionyl chloride. The mixture was held at 80 ° C for 20 minutes, after which the solvent was distilled off under reduced pressure. The residue is dissolved in 10 ml of toluene and the resulting solution is cooled to. A solution of 5 g of dl-oi-tocopherol in 4.25 m of pyridine is added dropwise to the solution with stirring over 1.5 hours. The precipitate is filtered off and the filtrate is washed successively with water, 1N. hydrochloric acid, again with water and with a saturated aqueous solution of sodium bicarbonate. The toluene is distilled off, and the residue is subjected to chromatography on a column filled with silica gel, using a mixture of benzene and ethyl acetate in a 4: 1 ratio as eluent. 1.3 g of dl-ci-gokoferil-5-ethyl picolinate are obtained as a yellowish oily liquid IR spectrum, pure max., Cm 2920, 2855, 1750, 1725, 1570, 1460, 1300, 1240, 1100, 755 7 NMR spectrum (SBSI3, 60 MHz), (Gr: 0.7-3.0 (t, 54H), 7.5 (q, III), 8.0 (d, 1H), 8.5 ( d, 1H). I In the same manner as in Example 1, using dl-oi-tocopherol and the corresponding 5-substitutable picolinic acid derivatives as the starting compounds, the following compound is obtained. dl-oi-Tocoferyl-5-n-hydroxypicylolONENET (Example 12). IR spectrum, h) pure max.,: 2920, 2850, 1755, 1725, 1570, 1460, 1300, 1240, 1100, 755. NMR spectrum (SCC, 60 MHz), LPRT: 0 7-3.0 (t, 62 H), 7.5 (q, 1H), 8.0 d, 1H), 8.5 (d, 1H). dl-o-Tocopheryl-5- (3-buten-1-yl) picolinate (Example 13). IR spectrum, -Or max., Cm: 2920, 2850, 1750, 1722, 1465, 1460, 1375, 1300, 1250, 1100, 1010, 905. NMR spectrum (CDGlj, 60 MHz), Ltrga: 0, 6-2.9 (ha, 53H), 5.1 (t, 2H), 5.5-5.9 (t, 1H), 7.7 (q, 1H), 8.2 (d, 1H ), 8.5 (d, 1H). Examples 14-17. In the same manner as in Example 1, using the starting compounds dl-oi-tocopherol and the corresponding 5-zinc rich picolinic acid derivatives, the following compounds are obtained. dl-c-Tocopheryl-5-butiloxypicalol nat (Example 14), melting point 46-48 C. IR spectrum, max. cm, 2920, 2850, 1755, 1725, 1580, 1475, 1465, 1380, 1320 , 1255, 1100. NMR spectrum (COCl 3, 60 MHz), SLrr: 0.6-2.8 (t, 56H), 4.1 (t, 2H), 7.3 (q, 1H), 8, 1 (d, W), 8.5 (d, 1H dl-oi-Tocopheryl-5-propyl xypolycolate (Example 15), melting point 55-57 ° C., IR spectrum, .-) pure max.,: 2920 , 2850, 1750, 1720, 1575, 1470, 1460, 1380, 1320, 1230, 1100. NMR spectrum (CDClj, 60 MHz), d ppm: 0.6-2.8 (t, 54H), 4.05 (t, 2H) 7.3 (q, 1H), 8.25 (d, 1H), 8.5 (d, 1H dl-oi-Tocopheryl-5- (4-chlorobutyloxy) -picolinate (Example 16). IR spectrum, -O pure max.: 2920, 2850, 1740, 1720, 1575, 1470, 1460, 1380, 1320, 1235, 1100, 1080. NMR spectrum (CDClj, 60 MHz), ppm: 0.6 - 2.8 (ha, 53H), 3.7 (t, 2H), 098 4.1 (t, 2H), 7.7 (q, W), 8.2 (d, 1H), 8.7 (d; 1H). Dl-c-Tocopheryl 5- (4-chlorophenyloxy) picolinate (Example 17). IR spectrum,} net max., Cm: 2920, 2850, 1740, 1720, 1605, 1570, 1460, 1380, 1320, 1235, 1100. NMR spectrum (CDClj, 60 MHz), sLrt: 0.6-2.8 (t, 49H), (q, 2H), 7.2 (q, 2H), 7.8 (q, 1H), 8.2 (d, 1H) 8.7 (d, 1H). Examples 18-24. In the same manner as in Example 1, using dl-o -tocopherol and the corresponding 5-substituted picolic acid derivatives as starting compounds, the following compounds are obtained. dl-di-Tokofersht-5-butylthiopicolinate (Example 18). IR spectrum, max max., Cm: 2-920, 2850, 1750, 1720, 1570, 1460, 1380, 1300, 1235, 1100. NMR spectrum (CDClj, 60 MHz), /-Hg: 0.6- 2.8 (t, 56H), 3.0 (t, 2H), 7.7 (q, W), 8.15 (d, W), 8.7 (d, 1H). dl-ot-Tokofepil-5-n-octylthiopicolinate (Example 19). IR spectrum, O pure max., 2920, 2850, 1750, 1722, 1565, 1470, 1460, 1380, 1310, 1230, 1100, 1070, 780. NMR spectrum (CDClj, 60 MHz), ppm: 0.6 -2.8 (t, 64H), 3.0 (t, 2H), 7.65 (q, III), 8.1 (d, 1H), 8.65 (d, 1H dl-o-Tocopheryl 5-isopentylthiopicolinate (example 20). IR spectrum, -O pure max., Cm: 2920, 2850, 1750, 1725, 1565,, 1460, 1380, 1305, 1240, 1100, 1020. dl - (- Tokoferil-5 -methylthiopicolate example 21). IR spectrum, J net max., cm: 2920, 2820, 1750, 1722, 1465, 1380, 1305, 1105, 1080. NMR spectrum (CDClj, 60 MHz), ppm: 0 , 6-2.8 (s, 49H), 2.55 (S, 3N), 7.75 (q, 1H), 8.23 (d, 1H), 8.73 (d, W). Dl- ) (- Tocopheryl-5-benzylthiopicolinate (Example 22). IR spectrum, O pure max., Cm: 2920, 2820, 1750, 1720, 1465, 1460, 1375, 1300, 1240, 1100. NMR spectrum (CDClj, 60 MHz), ppm: 0.6-2.9 ( m, 55H), 3.4 (t, 2H), 7.75 (q, 1H), 8.2 (d, W), 8.65 (d, 1H) .V 91 dl-tt-Tocclfepyl-5 - (3-chloropropnlthio) -picolinate (Example 23). IR spectrum, l) pure max., Cm: 2920, 2820, 1740, 1722, 1465, 1460, 1375, 1320, 1235, 1100, 1080. NMR spectrum (CDClj, 60 MHz), 0.6-2.8 (ha, 31H), 3.25 (t, 2H), 3.7 (t, 2H), 7.75 (q, 1H), 8.25 (d, 1H), 8.25. (d, 1H). dl-i-Tocopheryl-5-allythiopicoline (Example 24). IR spectrum, net max., Cm 2920, 2850, 1740, 1722, 1465, 1460, 1375, 1300, 1235, 1100, 1010. NMR spectrum (CDClj, 60 MHz), Gr: 0, L-2, 8 (ha, 49H), 4.2 (d, 2H), 5.0-5.5 (ha, 2H), 5.75-6.25 (t, 1H), 7.7 (q, 1H) , 8.2 (d, 1H), 8.5 (d, 1H). Example 25 1.97 g of propylthiopicplinic acid and 2.15 g of dl-oi-tocopherol are dissolved in 25 ml of methylene chloride and 2.06 g of dicyclohexylcarbodiimide is added to the resulting solution. The mixture is left overnight with stirring. The precipitated dicyclohexyl urea is filtered off and the methylene chloride is distilled off from the filtrate. The residue is subjected to chromatography on a column filled with silica gel using a mixture of benzene and ethyl acetate in a 4: 1 ratio as eluent. As a result, 2.05 g of dl-ot-tocopheryl-5-propylthiopicolinate is obtained in the form of a yellowish oily liquid. IR spectrum, net max., Cm: 2920, 2850, 1745, 2560, 1460, 1375, 1300, 1230, 1100. NMR spectrum (CDClj, 60 MHz), ppm: 0.6-2.8 (t , 54H), 3.0 (t, 2H), 7.7 (q, 1H), 8.2 (d, 1H), 8.7 (d, 1). It was established that the compounds of formula (1) when introducing them the body reduces blood pressure, has a prolonged effect of B, differs from the known 5-marked picolinic acid derivatives, they are not toxic and have no adverse effect. It was also established that new compounds can be used for the prevention and treatment of arteriosclerosis and thrombosis because they are similar to vitamin E have ant t rhombic and antiarterioscleral activity, exaggeration in inhibiting the formation or accumulation of 910 lipid peroxides, infect vascular tissues, improve lipid metabolism or prevent platelet aggregation. It is known that arteriosclerosis or thrombosis occurs easily on damaged vascular tissues and spreads very quickly. - It is believed that hypertonia can primarily cause thrombosis or ateriosclerosis. Therefore, to prevent serious diseases of the vascular system, in particular arteriosclerosis or thrombosis, patients with hypertension are required to ensure that their blood pressure is within the normal range, which is recommended drugs that lower blood pressure. Since patients with severe and other types of hypertension have to take blood pressure lowering drugs for a long time, it is necessary that these drugs have minimal toxicity and no adverse effect. It is desirable that they not only lower blood pressure, but also improve blood circulation, inhibit the formation or accumulation of lipid peroxides, inhibit the aging of vascular tissues, stabilize cell membranes, reduce the likelihood of blood clots or initiate microcirculation. The compounds of formula (I) meet the above requirements. Esters of 5-substituted picolinic acid lower blood pressure to the same extent as 5-substituted picolinic acid derivatives. Their activity, however, persists for a longer time. In addition, they are significantly less toxic compared to the 5-substituted picolinic acid and have no side effects. As a pharmaceutically acceptable diluent or carrier in pharmaceutical preparations, known liquid or solid diluents or carriers can be used to prepare various types of drugs. Examples of suitable solid diluents or carriers are lactose, corn starch, crystalline cellulose, carboxymethyl cellulose, hydroxypropyl cellulose, Arabic. ka gum, carnauba wax, beeswax and magnesium stearate, and liquid diluents or carriers - cune, olive, cottonseed, soybean oil, peanut oil, refined rice oil and propylene glycol. Pharmaceutical preparations are available in various forms, for example, in the form of soft or hard capsules, granules and tablets. The amount of the compound of formula (I) in pharmaceutical preparations may vary depending on the form in which the preparation is manufactured. Thus, for example, it may be from 20 to 100% based on the weight of the preparation. As a rule, preparations are taken orally. Their dosage ranges from 50 mg to 1.5 g, depending on the weight of the patient. Pharmacological tests were carried out using oi-tocopheryl-5-butyl picolinate, the most effective compound of formula Cl).
The tests were carried out as follows.
1. Decreased blood pressure.
1-c1.-Tocopheryl-5-butyl picolinate and dl-et-tocopherol were used after dissolving each of the n in the required amount of diethyl ether, mixing with a solution containing 2% Tween 80 and 2% Span 40, distilling the diesel ether, and emulsifying 5 - Butyl picolinic acid was applied in the form of a solution containing 2% Tween 30 and 2% Span 40.
Ppertonium rats, males weighing 350–370 g (Table 1) and Wistar rats with normal blood pressure (Table 2), were used as experimental animals. Each group consisted of three animals. The drug was administered orally. Blood pressure in the tail artery was determined without anesthesia using plethysmography. The results are shown in Table. 1 and 2 respectively.
In tab. 1 and 2, compound A means β1-o-tocopheryl-5-butyl picolinate, compound B — C-butyl picolinic acid, compound C is a mixture of 5-butyl picolinic acid and dl-et-tocopherol (the weight ratio of the components of the mixture is 2: 1, i.e. both components are taken in approximately equimolar amounts). The numbers in brackets in the Dose column are values calculated for 5 butyl picolinic acid.
From the listed table. 1 and 2 data shows that dl-oi-tocopher sh-5-butyl picolinate lowers blood flow
2. Acute toxicity tests.
Female mice weighing about 20 g of ddy breed (5 per group) were used as experimental animals. Each of the tested compounds was administered orally or intraperitoneally. After two days, the number of dead mice was determined. From the data obtained, the average lethal dose (iDjg) was determined according to the method of Behrens-Crahr. The results are shown in Table. 3
Compounds A, B, C, as well as the numbers in parentheses in Table. 3 have the same meanings as in Tables 1 and 2.
From the table. 3 results show that in groups of animals that were orally or intraperitoneally injected with the y1-a-tocopheryl-5-butyl picolinate, the death of the animals was not observed even with the introduction of the largest doses of 4000 mg / kg (1212 mg / kg in terms of 5-butyl picolin) acid). At the same time, for 5-butnolicic acid of one or its mixture with dl-c-dofluorol was 180 and 180 mg / kg, respectively, for oral administration, and 89 and 98 mg / kg for intraperitoneal administration (all data are in terms of 5 pressure in patients with hypertension of rats to about the same extent as 5-butyl picolinic acid or its mixture with dl-o (-tocopherol used as control drugs. At the same time, the effect of dl-d-tocopheryl-5-butyl picolinate on rats normal blood pressure is less pronounced compared to 5-butyl picolinic acid lotoy both the degree of pressure reduction, and on the duration of action. It follows that dl-o-5--tokofepil bytil- picolinate has greater selectivity for the treatment of hypertension than 5-butilpikolinova acid.
-butyl picolinic acid). in other words, the toxicity of 5-butyl picolinic acid did not decrease when it was simply mixed with ТT-x-tocopherol and markedly decreased when esterified with its dl-oi-tocopherol.
3, side effects.
1-o-tocopheryl-5-butyl picolinate in accordance with the present invention and 5-butyl picolinic acid iB as a control compound were orally administered to rats for. 4 days in an amount of 300 mg / kg (90.9 mg / kg based on 5-butyl picolinic acid) and 100 mg / kg. Then, the animals' stomachs were opened and examined for gastric diseases. In the stomachs of all animals of the control group (5 rats), mild swelling, hyperemia or bleeding was detected, while no changes were detected in the stomachs of rats injected with dl-tocopheryl-5-by-butylpicolic.
In tab. 4 and 5 show data on the maximum decrease in blood pressure and acute toxicity (LUj values) of other typical examples of compounds of formula (I).
In the process of testing, the data are given in table. 4, rats suffering from hypertension were orally administered at 0.01 mmol / kg of each test compound.
In the tests, the data are given in Table. 5, compounds
administered intraperitoneally to mice.
Comparative Example 1. 1.2 g of 5-mercaptopicolinic acid is dissolved in 100 ml of 5% aqueous sodium carbonate solution and 100 ml of acetone, 4.4 g of anhydrous sodium carbonate and 3.0 g of n-butyl bromide are added to the resulting solution. . The mixture is stirred at room temperature.
temperature for 3 hours, after which acetone is distilled off from it under reduced pressure. To neutralize the residue, hydrochloric acid is added to pH 2.0, and then extraction is carried out with ethyl acetate. After recrystallization of the extract from an aqueous solution of ethanol, 0.85 g of 5-n-butylthiopicolinic acid with a melting point of 99 ° C is obtained.
The concentration of the product obtained, at which 50% inhibition of dopamine-hydroxylase activity was observed, is 5.1 x
LDj, 180 mg / kg.
Comparative example 2. Listed in table. 6 compounds are prepared in the same manner as in comparative example 1. Temperatures
the melting of these compounds, the solvents from which the recrystallization is carried out, and the concentrations of the compounds, at which 50% inhibition of dopamine is observed, are shown.
in tab. 6
Table 1
37.5 (11.36)
9,375 (2,841)
12.5 (12.5)
3.125 (3.125)
37.5 (12.5) 9.375 (3.125)
13.0
About About About About About
About 11.8
About 16.4
5.5
CH,
T a b l n c h
Table 3
41
39
17
CHj (CHj) j
18
1151209
Continuation of table 4
4,000
134

权利要求:
Claims (1)
[1]
METHOD FOR PRODUCING οί-TOCOPHYRYL ETHERS OF 5-SUBSTITUTED PICOLIC ACID of general formula I n _} with CoC ₅ (CHiCHiCHiCH) jCHj
CHj CH3 in the presence of a dehydrocondensing agent.
Priority by signs:
05/26/81, with Q - methylene group, R - plopil or butyl;
04/13/82, when Q is a methylene group or an oxygen or sulfur atom, R is lower alkyl, unsubstituted or substituted, lower alkenyl, phenyl (lower) alkyl or substituted phenyl, provided that when R is propyl or butyl, Q is not methylene group.
SU „1151209
1151> O9

类似技术:

---

公开号 | 公开日 | 专利标题

---

CA2259621C|2007-09-18|Isocoumarin derivatives and their use in medicines

---

EP0202589B1|1990-02-28|Pharmaceutical compositions containing ascorbic acid derivatives

---

US4483867A|1984-11-20|Antifibrinolytically active derivatives of tranexamic acid

---

SU1151209A3|1985-04-15|Method of obtaining alpha-tocopheryl esters of 5-substituted picoline acid

---

US4616025A|1986-10-07|Thiazolidine derivatives, process for the preparation and pharmaceutical compositions thereof

---

EP1369419B1|2007-05-23|N-phenylarylsulfonamide compound, drug containing the compound as active ingredient, intermediate for the compound, and processes for producing the same

---

US3987177A|1976-10-19|Vincaminic acid esters

---

DK172879B1|1999-09-06|Silibinin-containing pharmaceutical composition

---

EP1142885B1|2006-11-15|2-|thiazolidin-4-one derivatives

---

JP2691679B2|1997-12-17|Oxime derivative and pharmaceuticals containing the same

---

WO2012011112A1|2012-01-26|Non psychoactive cannabinoids and uses thereof

---

KR100281867B1|2001-02-15|3- | oxindole derivatives

---

CA1240332A|1988-08-09|Pyridine derivatives and process for preparing thesame

---

US4134991A|1979-01-16|Derivatives of 2-|-acetic acid

---

EP0087629A2|1983-09-07|Antiinflammatory and/or analgesic 2,3-Diaryl-5-halo thiophenes

---

FR2521992A1|1983-08-26|NOVEL PYRIDINE COMPOUNDS USEFUL AS MEDICAMENTS

---

EP0419676A1|1991-04-03|Thionaphthalene derivatives, method of producing the same, and antiallergic agent containing the same

---

EP0429464B1|1994-11-23|Bivalent ligands effective for blocking acat enzyme

---

EP1762558A1|2007-03-14|Process for preparing transcription factors and their use

---

EP0787494A1|1997-08-06|Remedy for diseases caused by infection with helicobacter

---

GB2171997A|1986-09-10|4-Amino-6,7-dimethoxy-2-Piperazin-1-ylquinazoline derivatives

---

WO2002092614A1|2002-11-21|Novel 5-thio-ss-d-xylopyranoside derivatives, preparation method thereof, pharmaceutical compositions containing same and the therapeutic use thereof

---

EP0772630A1|1997-05-14|Streptogramine derivatives, preparation of same and pharmaceutical compositions containing same

---

JPH07206838A|1995-08-08|New ascofuranone derivative and blood lipid-lowering agent, hypoglycemic agent, glycation-inhibiting agent and antioxidizing agent containing the same as active ingredient

---

US4044135A|1977-08-23|Antihypertensive agents

同族专利:

---

公开号 | 公开日

---

EP0066242A1|1982-12-08|

---

HU189584B|1986-07-28|

---

US4443459A|1984-04-17|

---

DE3265217D1|1985-09-12|

---

EP0066242B1|1985-08-07|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

US5118694A|1987-07-06|1992-06-02|Hoffmann-La Roche Inc.|Benzopyran derivatives|FR6320M|1967-04-12|1968-09-23|

---

US4198416A|1976-09-30|1980-04-15|Meiji Seika Kaisha, Ltd.|5-Alkoxy-picolinic esters and anti-hypertensive composition containing 5-alkoxy-picolinic esters|US6441009B1|1998-08-01|2002-08-27|Novactyl, Inc.|Agent and method of preventing and treating heavy metal exposure and toxicity|

---

US6743771B2|1995-12-29|2004-06-01|Novactyl, Inc.|Methods and compositions for controlling protein assembly or aggregation|

---

US6127393A|1995-12-29|2000-10-03|Novactyl, Inc.|Antiproliferative, antiinfective, antiinflammatory, autologous immunization agent and method|

---

US6579891B1|1995-12-29|2003-06-17|Novactyl, Inc.|Agent and method for prevention and treatment of cancer in animals|

---

US6407125B1|1995-12-29|2002-06-18|Novactyl, Inc.|Pharmacological agent and method of treatment|

---

US6403618B1|2000-02-15|2002-06-11|Novactyl, Inc.|Agent and method for controlling angiogenesis|

---

US6806259B2|2001-12-21|2004-10-19|Soft Gel Technologies, Inc.|Hyaluronic Acid in soft gel form|

---

JP4212970B2|2003-06-30|2009-01-21|株式会社キーエンス|Safety relay system|

---

US20050186269A1|2004-02-25|2005-08-25|Udell Ronald G.|Stabilized feverfew formulations|

---

US20080268039A1|2007-03-06|2008-10-30|Soft Gel Technologies, Inc.|Loquat compositions|

---

CN106243024B|2016-07-29|2018-06-19|河南省农业科学院芝麻研究中心|The method that fusaric acid and dehydrogenation fusaric acid are detached from wilt toxin|

法律状态:

优先权:

---

申请号 | 申请日 | 专利标题

---

JP56078702A|JPS6356227B2|1981-05-26|1981-05-26|

---

JP6035982A|JPS58177988A|1982-04-13|1982-04-13|Alpha-tocopheryl 5-substituted-picolate and its preparation|

---